S-1单药或联合方案治疗转移性肺癌的疗效和安全性

Efficacy and safety of regimens of S-1 based chemotherapy in the treatment of metastatic lung cancer

目的:探讨S-1单药或联合方案治疗转移性肺癌的疗效和安全性。方法:36例转移性肺癌患者接受如下方案治疗:S-1单药组:S-1用量为40mg/m2,口服,bid,第1-14天,21天为一个周期。S-1联合多西他赛组(TS方案):S-1用量为40mg/m2,口服,bid,第1-14天,多西他赛75mg/m2,静脉滴注,第1天;21天为一个周期。结果:S-1单药组患者的ORR为14.3%,CBR为35.7%,而S-1联合多西他赛组ORR为22.7%,CBR为72.7%,两组ORR差异无统计学意义(P>0.05),CBR差异有统计学意义(P<0.05)。结论:S-1单药或者含S-1联合方案是转移性肺癌治疗的有效选择方案,患者不良反应可耐受。

Objective： To evaluate the efficacy and toxicity of S - 1 based chemotherapy in the treatment of meta- static lung cancer. Methods：Thirty - six patients with metastatic lung cancer were treated with S - 1 based chemo- therapy regimens. They were divided into 2 groups, group 1 was treated with S - 1 40mg/m^2 orally twice daily on d1-14, repeated every 3 weeks, group 2 was treated with S - 1 as group 1, and combined with docetaxel 75mg/m^2 intra- venous infusion on d1 , repeated every 3 weeks. The median treatment period of treatment was 3 cycles. Results ： In group 1 the objective response rate（ORR） was 14.3% and clinical benefit rate（CBR） was 35.7%. In group 20RR was 22.7 % , CBR was 72.7 %. There was significantly difference in CBR between 2 groups （ P 〈 0.05 ）. Conclusion ： S - 1 based chemotherapy is effective and tolerable for metastatic lung cancer.